Compare ALDX & BGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALDX | BGT |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.0M | 320.3M |
| IPO Year | 2014 | N/A |
| Metric | ALDX | BGT |
|---|---|---|
| Price | $4.56 | $11.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.50 | N/A |
| AVG Volume (30 Days) | ★ 953.0K | 107.2K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.77% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $36.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.14 | $10.89 |
| 52 Week High | $7.20 | $13.42 |
| Indicator | ALDX | BGT |
|---|---|---|
| Relative Strength Index (RSI) | 39.04 | 40.82 |
| Support Level | $4.67 | $11.05 |
| Resistance Level | $5.04 | $11.34 |
| Average True Range (ATR) | 0.29 | 0.12 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 3.42 | 54.72 |
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Blackrock Floating Rate Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income. The company's secondary investment objective is to seek the preservation of capital. The Trust seeks to achieve its investment objectives by investing mainly, under normal conditions, at least 80% of its assets in floating and variable rate instruments of U.S. and non-U.S. issuers, including a substantial portion of its assets in floating and variable rate securities including senior secured floating rate loans made to corporate and other business entities.